Chronic Myelogenous Leukemia

ChronicMyelogenous Leukemia

ChronicMyelogenous Leukemia

Inthe article “ChronicMyeloid Leukemia: Practical Issues in Diagnosis, Treatment andFollow-Up”,the authors acknowledge that chronic myeloid leukemia is seen asbeing the disease of firsts. Indeed, the disease was the first one tohave the term “leukemia” used and doubled up as the firstneoplastic disorder whose association with recurrent chromosomalabnormality was determined. Further, the ailment comes as the firstone to have targeted therapy being used against fusion protein(Buyukasik et al, 2010). Nevertheless, the authors acknowledge therelative lack of information among patients with regard to the typesof treatment available for the condition. Indeed, the article reviewsand summarizes practical points regarding chronic myeloid leukemiawhile particularly emphasizing or focusing on treatment for theailment and subsequent follow-up. The authors acknowledge that theintroduction of BCR-ABL tyrosine kinase inhibitors, the firstlmanitib, then dasatinib and then nilotinib to the clinical practicein the last one decade has essentially altered both treatment and thefollow-up of the ailment (Buyukasik et al, 2010). Unlike otherchronic leukemic disorders, rarely is CML diagnosed in asymptomaticindividuals conditions that cause leukemoid blood picture alongsidesome myeloproliferative disorders and myelodysplastic neoplasms areoften considered in the varying diagnosis of the condition. In thetreatment of the condition, the authors particularly examine the useof iminitib or Glivec, Norvatis among other tyrosine kinaseinhibitors (TKIs). The treatment is examined in categories such asfirst-line treatment, second-line treatment advanced ailment andfollow up, with particular emphasis on imatinib (Buyukasik et al,2010). Indeed, the authors detail the cases where the patientresponds to imatinib in a suboptimal manner and the conditions inwhich this occurs.

Inthe article “Treating Chronic Myeloid Leukemia: ImprovingManagement Through Understanding of the Patient Experience”,Cheryl-Anne Simoneau acknowledges the numerous options that areprovided by the immense progress that has been made in the treatmentof chronic myeloid leukemia (Simoneau, 2013). Indeed, a number ofBCR_ABL inhibitors from the basic CML treatment were recentlyapproved into the market. Research has shown that nilotinib anddasatinib incorporate immensely higher efficacy compared to theimatinib in the first-line chronic phase CML, thereby enablingpatients to have more rapid and deeper responses that are linked toimproved outcomes. The increased information and the numerousalternatives to the imatinib in first-line CML-CP, there comes animmense need for accurate and clear facts that would assistindividuals to make decisions pertaining to their treatment(Simoneau, 2013). The author acknowledges the valuable nature ofoncology nurses capable of clearly explaining emerging datapertaining to the significance and meaning of deeper and fasterresponses. Varied patient issues are also examined in the paperincluding the management of side effects, adherence to treatment,access to drugs, patient education and changes in lifestyle(Simoneau, 2013). In addition, the author examines the extent ofeffects of CML drugs on the patient’s quality of life. In thisregard, the author examines a particular survey where patientsreported improved quality of life despite the varied side effects ofthe CML drugs.

Thesetwo articles provide crucial information that would be immenselyhelpful in my life. This is especially considering the fact that I ama chronic myeloid leukemia survivor. Indeed, the information providedin the two articles gives me better comprehension of the disease andthe available forms of treatment. As much as the information providedmay be too scientific especially in the case of the first article, itgoes without saying that I would be imparted with knowledge regardingthe kind of questions that I should have asked regarding thetreatment.

Inaddition, the articles provide me with more insight regarding thevaried side effects that I experienced in the course of treatment.The varied treatment options that are currently available providegreater possibilities for reduced side effects. Of particular note isthe fact that patients can make fundamental modifications in theirlifestyles so as to assist in lowering the side effects and offerlife-affirming goals. Indeed, the modification of routine may resultin higher adherence with the formation of new habits. For instance, Iused to experience fatigue, a condition that would have been improvedby taking up an exercise program that balances the right activitylevels with rest.

Oneof the key similarities between the articles and the informationprovided in book is the fact that both acknowledge the importance ofcollaboration between patients and their caregivers. Indeed, improvedpatient-physician relationship would have a bearing on the quality ofcare that is provided to the patient and the possibility that thepatient recovers (Sheldon,2012)(Ireland,2013).This is especially considering that such relationships enhance thelevels of trust and communication, which, undoubtedly, result inimproved care (Balint, 2000). It is well acknowledged that improvedcommunication would enhance collaboration between the two individualsand increase the possibility that the patient would ask questionswhere he or she does not understand and provide information regardingany side effects that he or she is experiencing (Sheldon,2009)(Ireland,2013).This collaboration has always been emphasized on as it allows forimproved care and increases the chances for recovery.

References

Balint,M (2000).Thedoctor, his patient and the illness.(2000). Edinburgh: Churchill Livingstone.

Buyukasik,Y., Haznedaroglu, I.C &amp Ilhan, O (2010). Chronic MyeloidLeukemia: Practical Issues in Diagnosis, Treatment and Follow-Up.InternationalJournal of Hematology and Oncology,Number: 2 [Suppl 1] Volume: 20

Ireland,K. A. (2013).&nbspVisualizinghuman biology.Hoboken,NJ : Wiley

Sheldon,L. K. (2009).&nbspCommunicationfor nurses: Talking with patients.Sudbury, Mass: Jones and Bartlett Publishers.

Sheldon,L. K. (2012).&nbspCommunicationfor nurses: Talking with patients.Boston: Jones and Bartlett.

Simoneau,C.A (2013). Treating Chronic Myeloid Leukemia: Improving ManagementThrough Understanding of the Patient Experience. ClinicalJournal of Oncology Nursingt Volume 17, Number 1